In conclusion, we identify SERT as an immune checkpoint negatively regulating CD8 T cell antitumor immunity through modulating intratumoral T cell-autocrine serotonin and demonstrate the potential of targeting the intratumoral serotonin axis using SSRI antidepressants for T cell-based cancer immunotherapy. The gene discussed is SLC6A4; the disease is cancer.